BACKGROUND: Agonistic angiotensin II type 1 receptor autoantibodies (AT1RaAbs) have not been associated with functional measures or risk for adverse health outcomes. AT1RaAbs could be used to stratify patient risk and to identify patients who can benefit from angiotensin receptor blocker treatment.
T he Renin-Angiotensin System (RAS) has been identified in subcellular organelles such as the nucleus and mitochondria, in organisms without a pressurized vasculature, and in virtually every human organ system. 1, 2 An independently regulated RAS in human monocytes has been identified. 3 Beyond its classic role in homeostatic regulation of blood pressure and fluid balance, the RAS has been implicated in tissue remodeling and wound repair. 4 Binding of angiotensin II, the main effector hormone, to the angiotensin II type 1 receptor (AT1R) increases the production of inflammatory molecules and regulates multiple steps in the inflammatory process. 5 Inappropriate activation of the RAS may contribute to chronic inflammation, but how this occurs is not fully understood.
Autoantibodies that react with the AT1R (AT1RaAbs) and increase expression and function of the receptor in an apparent positive feedback loop have been identified in preeclampsia 6 and have been linked to transplant rejection and malignant hypertension. 7, 8 A proinflammatory cascade, initiated by AT1RaAbs, has been proposed which involves antibody binding, signal transduction through ERK1/2, an increase in reactive oxygen species, NADPH oxidase expression, and nuclear factor-ĸB activation. 9 Activation of this proinflammatory pathway has been suggested as a potential mechanism for endothelial damage observed in persons with hypertension and cardiovascular disease. 10, 11 A frailty phenotype, assessed by using a validated clinical tool, identifies older adults who are particularly vulnerable to a host of adverse health outcomes including falls, functional decline, disability, cardiovascular events, and early mortality. Substantial evidence supports associations between this phenotype and markers of chronic inflammation (neutrophil, monocyte, and total white blood cell counts and interleukin-6 [IL-6] levels). 12 How inflammatory activation is sustained remains poorly defined, but multiple chronic disease states, redox imbalance, senescent cells, and increased body fat have been suggested. 13, 14 We hypothesized that levels of AT1RaAb would be associated with increased inflammation, deficits in functional measures (grip strength and walking speed), and negative outcomes (increased frailty and falls). This hypothesis was tested in a primary population of community-dwelling individuals (the Baltimore group). A secondary group (the Chicago group) was used to validate associations between AT1RaAb levels and functional measures and outcomes observed in the Baltimore group. Angiotensin receptor blockers (ARBs) provide cardiovascular protection, in part, through their vascular and anti-inflammatory effects. 15 Whether ARB treatment can modify the associations between AT1RaAb and functional measures and outcomes is unknown. The Chicago group, half of whom were ARB treated, was also used to explore how ARB treatment impacts AT1RaAb associations.
METHODS Study Design and Participants
Two hundred fifty-five community-dwelling adults, 20 to 93 years of age, living in the Baltimore, Maryland, area were recruited with the goal of developing a discovery set with an age range of 8 decades. Exclusion criteria included ARBs, angiotensin-converting enzyme inhibitors, estrogen replacement therapy, corticosteroids, methotrexate, and nonsteroidal anti-inflammatory drugs or other immune-modulating agents. On the basis of the distribution of AT1RaAbs, subjects were divided into 2 groups: adult (20-69 years of age, n=168) and older adult (>70 years, n=87). A uniform structured clinical evaluation was performed on each older adult participant to identify low-risk and high-risk individuals. At-risk status was assessed by using a commonly used and well-validated frailty phenotype screening tool that consists of grip strength and walking speed measurements, and weight loss, fatigue, and physical activity questions, as well. 16 To replicate our findings from the Baltimore group, convenience samples were obtained from the Religious Orders Study and the Rush Memory and
Clinical Perspective
What Is New?
• A quantitative immunoassay for measuring agonistic angiotensin II type 1 receptor autoantibody (AT1RaAb) levels in serum was developed.
• Operating characteristics were assessed in a discovery group (N=255) and validated in a second group (N=60).
• AT1RaAb levels significantly associated with higher levels of inflammatory cytokines, weaker grip strength, slower walking speed, risk for frailty, more falls, and increased mortality.
• Chronic treatment with angiotensin receptor blockers attenuated the AT1RaAb association with decline in grip strength and increased mortality. • This study is the first to examine associations between serum AT1RaAbs with demographic, physiological, and functional covariates and outcomes.
What Are the Clinical Implications?
• Chronic inflammation commonly accompanies frailty and increases the risk of cardiovascular events and death in older patients.
• Stimulatory AT1RaAbs may increase inflammatory burden, potentially accelerating disease progression.
• Follow-up studies in intervention trials in serious diseases whose underlying pathology involves chronic inflammation could test whether these AT1RaAb levels can be used to stratify patient risk across a broad spectrum of disorders and whether they may identify patients who can benefit from angiotensin receptor blocker treatment and those that would benefit from other treatment modalities.
ORIGINAL RESEARCH ARTICLE

451
Aging Project, longitudinal clinical-pathological studies of chronic conditions of old age. 17, 18 In these studies, participants 70 to 90 years of age were recruited from residential facilities across the metropolitan Chicago area, including subsidized senior housing facilities, retirement communities, and retirement homes, in addition to social service agencies and church groups. Study subjects were enrolled with informed consent and the study protocols had appropriate approval by the Johns Hopkins Medical Institutional Review Board (for the Baltimore group) and Rush University Institutional Review Board (for the Chicago group).
Chicago participants underwent annual detailed clinical evaluations and were followed until death. The Chicago group did not have at-risk status assessed on subjects using the complete Fried criteria for frailty. Subjects did, however, have grip strength and walking speed measured. The number of samples needed from the Chicago group were assessed by performing a sample size calculation by using the observed mean functional measures (grip strength and walking speed) above and below the assessed optimal AT1RaAb serum level cutoff value in the Baltimore population, the standard deviation of those measures, and an 80% power to detect the relevant difference between means at a significance of 0.05. For grip strength, a mean difference of 11 kg, an observed standard deviation of 12, yielded a sample size of 20. For walking speed, a mean difference of 0.31 m/s, a standard deviation of 0.41, yielded a sample size of 30 per group. The larger sample size was used. The convenience samples were from baseline, and onehalf of the samples were from subjects treated with ARBs. To minimize confounding between ARB-exposed and unexposed groups, serum samples were selected from subjects who were individually matched. A subject who did not receive ARBs was matched to a subject who received ARBs by age (±2 years), sex, ethnicity, body mass index (BMI; ±2 kg/m 2 ), and blood pressure (±10 mm Hg). All samples in the validation set were from subjects with confirmed deaths. Data collected on subjects from both groups included demographic (age, sex, ethnicity), physiological (BMI, blood pressure, comorbid conditions, medications), functional (grip strength and walking speed), and outcome (falls and mortality) measures. All data are cross sectional, with the exception of the falls and mortality data.
Procedures
Blood collection visits were scheduled in the morning. Blood was drawn from each individual participant into serum separator tubes which were inverted 5 times, allowed to clot for 30 minutes, and centrifuged at 1100g for 15 minutes in a fixedangle rotor. Serum aliquots were then transferred to cryovials and stored at -80°C until the immunoassays were performed. The number of freeze-thaw cycles was limited to ≤3. A quantitative antigen-down capture enzyme-linked immunosorbent assay (ELISA) was developed in-house to measure AT1RaAb in serum samples (see below). Serum IL-6 was assayed using a quantitative sandwich ELISA (Mesoscale Diagnostics) following the manufacturer's protocol. Performance characteristics of the cytokine immunoassay included a lower limit of detection (LLOD) of 0.09 pg/mL, and a lower limit of quantitation (LLOQ) of 0.30 pg/mL.
A quantitative AT1RaAb ELISA was developed using purified capture antigen, AFHYESQ, which was coated at 100 ng/well in 0.2 mol/L sodium carbonate/bicarbonate buffer, pH 9.4, overnight at 4°C. Wells were blocked with Neptune blocking reagent (ImmunoChemistry Technologies). Serum from subjects was diluted 1:200, serum and antibody dilutions were made in Tris-buffered saline containing 0.05% Tween 20 and 10% Neptune blocking reagent. Each subject had duplicate aliquots on coated and uncoated wells; thus, the assay measures both specific and nonspecific binding for each subject. Additional wells (half antigen coated and half uncoated) were reacted with serial dilutions of an affinity purified, goat anti-rabbit anti-FHYESQ immunoglobulin G (IgG) antibody (Biorbyt LLC) to generate a standard curve. A 1:2000 dilution of a secondary goat anti-human IgG detection antibody conjugated to horseradish peroxidase was used in conjunction with 3,3′,5,5′-tetramethylbezidine substrate (Kirkegaard & Perry Laboratories).
For interpolating the values of unknowns, standards of the anti-FHYESQ IgG antibody serially diluted from 133 ng/mL and linear regression were used. Samples with calculated values above the highest standard were further diluted and reanalyzed in the ELISA. In addition, if the coefficient of variance of unknown sample replicates exceeded 15%, the sample was also reanalyzed. The coefficient of variance among sample replicates ranged between 5% and 15%, with higher coefficients of variance clustering at the low end of the curve. Three serum samples, with AT1RaAb levels of 20.2, 10.0, and 4.9 µg/mL, were analyzed in triplicate and the coefficients of variance were assessed to be 12%, 9.4%, and 14.6%, respectively. Assay parameters including the LLOD and LLOQ were assessed following methodology proposed by the International Council for Harmonization. 19 A LLOD of 2.5 ng/mL was calculated using the formula LLOD=3.3σ/S, where σ is the standard deviation of the y-intercept of the regression line and S is average slope of 9 standard curves, whereas a LLOQ of 7.4 ng/mL was calculated using the formula LLOQ=10σ/S.
Three complementary methods were used to determine the presence, identity, and specificity of AT1RaAbs in serum. Surface plasmon resonance was used to detect binding of serum components to an antigenic peptide as described. 20 In brief, the antigen, AFHYESQ, was covalently attached via amine coupling to sensor chip CM5, perfused in 10 mmol/L HEPES, 150 mmol/L NaCl, 0.005% surfactant P20, pH 7.4, and reacted with 1:100 or 1:1000 dilutions of serum from an 81-year-old female serum donor. In between injections, the chip was regenerated with 10 mmol/L glycine-HCl, pH 1.5. The identity of serum antibodies was assessed by Western blot analysis. The serum from an 81-year-old female donor diluted 1:500 was tested for immunoreactivity against extracts from 3 human-derived cell lines that were known to express AT1R (PC-3, DU145, and LNCaP) and a cell line, PC12W, as well, that did not express AT1R. 21, 22 The molecular mass of the immunoreactive bands was assessed following 4% to 20% gradient polyacrylamide gel electrophoresis of 50 µg/well cell lysate, transferring resolved proteins to a nitrocellulose membrane, using the serum to probe the membrane and detecting bound antibodies by a goat-anti-human IgG conjugated to horseradish peroxidase as described. 23 Last, the ability of soluble antigen to compete for binding with serum antibodies was tested using a competition assay. Serum from the same 81-year-old female donor, diluted 1:200, was preincubated with varying concentrations of AFHYESQ for 30 minutes at room temperature before transfer to AT1RaAb ELISA microtiter wells. The ELISA was then processed as described above to quantify the levels of autoantibodies binding to the capture antigen-coated wells. Receiver operating characteristic curve analysis was used for predicting at-risk status and identifying the optimal cutoff value of AT1RaAb on the basis of the Youden J statistic. Pairwise correlations between AT1RaAb and clinical correlates or functional outcomes were assessed using Spearman rank correlations. Logistic regression analysis was used to assess the association between AT1RaAb levels and high risk in the Baltimore group and falls in the Baltimore and Chicago groups. Multivariable-adjusted random-effects models were used to assess the association of AT1RaAb levels with continuous measures (grip strength and walking speed). The association of AT1RaAb levels with mortality was assessed by regression of the natural logarithm of time to death as a function of AT1RaAbs. Modeling log survival time was chosen because it is a special case of the accelerated failure model without censoring, because all subjects from the validation sample died; therefore, time to death was known for everyone in the study and the parameters of the model can be validly estimated via a conventional linear regression approach. The regression analyses were split by ARB treatment to assess the effect of ARBs on AT1RaAb associations with functional measures and outcomes. The statistical software used was SAS version 9.2 and a P≤0.05 was taken as supporting rejection of the null hypothesis.
Statistical Analysis
RESULTS
The epitope of AT1RaAbs has been localized to the sequence AFHYESQ in the extracellular loop 2 region ( Figure 1A) . 24 The binding of serum components to AF-HYESQ was investigated by surface plasmon resonance where the peptide was immobilized on the chip surface and different dilutions of human serum were injected in the mobile phase. Sensorgrams exhibiting the classic association and dissociation phases of a binding interaction were seen in each plot ( Figure 1B) . The same serum sample was used to probe a Western blot of SDS-PAGEresolved cell lysates from cell lines either known to express or not express AT1R. The major immunoreactive band exhibited a molecular weight of 43 000 similar to AT1R, whereas the negative control revealed no immunoreactive bands ( Figure 1C) . To quantify the levels of AT1RaAb in serum, an antigen-capture ELISA was developed. The assay used a rabbit anti-FHYESQ IgG antibody as a standard and conditions that gave a reproducible linearity up to 133 ng/mL ( Figure 1D ). The peptide AF-HYESQ was able to block the binding of serum autoantibodies to microtiter wells, yielding a dose-dependent reduction in levels of AT1RaAb measured by the ELISA in competition assays ( Figure 1E ).
Demographic and clinical variables of the discovery and validation groups are presented in Table 1 . For both groups, individuals >70 years of age were more likely to be female and had increased values for systolic blood pressure, number of comorbidities, BMI, and IL-6. a varied scatter when analyzed as a function of age (Figure 2A) . When AT1RaAb values were grouped by decade of life, there was no significant change in median values until after age 70 ( Figure 2B) . A Kruskal-Wallis ANOVA with the Dunn multiple comparisons test assessed that AT1RaAb levels from subjects in their 70s and 80s were significantly higher than those in earlier decades, P<0.0001. To further investigate this jump in AT1RaAb levels in adults >70 years of age, this group (older adult) was further segregated by using the Fried frailty criteria to distinguish between low-risk and high-risk individuals. High-risk older adults had higher median levels, 9.0 (range 2.8-20.3) µg/mL, of serum AT1RaAb in comparison with either the adult or low-risk older adults, 3.8 (range 0.3-18.5) µg/mL and 6.0 (range 1.6-17) µg/mL, respectively ( Figure 2C ).
Receiver operating characteristic curve analysis for detecting high-risk versus low-risk status in older adults yielded an area under the curve of 0.76±0.05 and, at a cutoff value of 8.2 µg/mL, a specificity of 80% (95% confidence interval [CI], 69-88) and sensitivity of 61% (95% CI, 41-78). On the basis of the receiver operating characteristic curve analysis, on average, the high-risk (frail) individuals will be correctly classified as such 76% of the time by using the 8.2 µg/mL AT1RaAb cutoff. Logistic regression analysis revealed that individuals with AT1RaAb levels >8.2 µg/mL were 3.9 (95% CI, 1.38-11.0) times more likely to be at high risk after adjusting for age (P<0.05). When analyzed in prespecified age groups, individuals aged 70 to 75 years, with AT1RaAb ≥8.2 were 4.88 (95% CI, 1.50-18.86) times more likely to be at high risk (P<0.01) than those with AT1RaAb <8.2 µg/mL. Among individuals who are >75 years of age, those with AT1RaAb ≥8.2 µg/mL were 9.0 (95% CI, 1.3-63.8) times more likely to be at high risk than those with AT1RaAb <8.2 µg/mL (P<0.05).
To further characterize the differences between the adult and low-and high-risk older adult groups, the distribution of IL-6, BMI, and blood pressure were analyzed ( Figure 2D through 2G) . Individuals >70 years of age exhibited significantly elevated IL-6, BMI, and systolic blood pressure (BP) in comparison with adults <70 years of age. High-risk individuals had higher levels of serum IL-6 with a median value of 1.7 (range, 0.7-9.0) pg/mL versus 1.1 (range, 0.5-3.2) pg/mL for low-risk subjects, P<0.01. High-risk older adults also had significantly higher median BMI values than low-risk older adults. The association between AT1RaAb and IL-6, BMI, and BP was investigated (Figure 3 ). Across all 3 groups (adults and older adults at low or high risk) there was a strong positive correlation between AT1RaAb and IL-6 (Spearman r=0.33, P<0.0001). Serum levels of AT1RaAb Older adult high-risk status has been strongly associated with weaker grip strength and decline in walking speed, and with increased falls and mortality, as well. 16, 25 The association between AT1RaAb levels and functional measures and outcomes was investigated in low-and high-risk older adults from the primary population in Baltimore ( Figure 4A through 4C) The number of subjects who had ≥1 falls was 12 and 16, respectively, for subjects with <8.2 µg/mL or ≥8.2 µg/mL AT1RaAb. The mean number of falls per subject was 0.80±1.1 for subjects with <8.2 µg/mL AT1RaAb levels and 1.70±1.80 for subjects with ≥8.2 µg/mL AT1RaAb levels (P<0.05 by unpaired t test with the Welch correction). Logistic regression of falls as a function of AT1RaAb levels yielded an odds ratio of 1.25 (95% CI, 1.06-1.47) unadjusted, 1.28 (95% CI, 1.07-1.47) for age-adjusted, and 1.33 (95% CI, 1.06-1.66) for age, sex, BMI, and BP-adjusted models. For every 1 µg/mL change in AT1RaAb levels, the odds of falling increased ≈30%. Mortality was too low (6%) in the Baltimore group to enable modeling of the association between time to death and serum AT1RaAb levels.
For the Chicago group, samples from 60 subjects, half treated with ARBs, had their associated demographic and physiological covariates, physical function tests, health outcomes, and AT1RaAb levels analyzed. The Chicago group had a higher average age, proportion of females, number of comorbidities, and reduced grip strength and walking speed in comparison with the Baltimore group (Table 1) A, Serum levels of AT1RaAb assessed by antigen capture ELI-SA were plotted as a function of individual donor age and sex (○, female; □, male). B, AT1RaAb levels graphed by grouping in decades. C, Serum levels of AT1RaAb in participants were segregated by age and risk status: adult, older adult low risk, older adult high risk. Serum levels of IL-6 (D), and measures of BMI (E), systolic (F) and diastolic (G) blood pressure in participants were segregated by risk status. Data points represent mean values of duplicate measures in each subject. Bar represents median value. Groups were compared by Kruskal-Wallis with the Dunn multiple comparisons test. AT1RaAb indicates angiotensin II type 1 receptor autoantibody; BMI, body mass index; ELISA, enzyme-linked immunosorbent assay; and IL-6, interleukin-6. speed (P<0.05 by unpaired t test with the Welch correction). The number of subjects who had ≥1 falls was 21 and 25, respectively, for subjects with <8.2 µg/mL or ≥8.2 µg/mL AT1RaAb. The mean number of falls per subject was 1.5±1.2 for subjects with <8.2 µg/mL AT1RaAb levels and 1.8±1.6 for subjects with ≥8.2 µg/ mL AT1RaAb levels (not significantly different). Logistic regression of falls in the Chicago group as a function of AT1RaAb levels yielded an odds ratio of 1.31 (95% CI, 1.01-1.69), although any adjustments made the association no longer significant.
These observations of an association between generalized weakness (slower walking speed and weaker grip strength) and higher AT1RaAb levels led to an investigation of the impact of AT1RaAbs on outcomes in the Chicago group. Regression analysis of the natural logarithm of time to death in the Chicago group yielded an unadjusted β AT1RaAb of -0.097 (95% CI, -0.150 to -0.044) with P<0.005. Adjusting for age, sex, and BMI did not significantly alter the association because β AT1RaAb was -0.096 (95% CI, -0.255 to -0.036) with P<0.01. For every 1 µg/mL increase in AT1RaAbs, the time to death decreased by 9% after adjusting for age, sex, BMI, and BP.
The associations of AT1RaAbs with functional and outcome measures in older individuals may by modified by ARB treatment because ARBs may compete with AT1RaAbs for receptor occupancy. Multiple-adjusted models were used to explore the effect of ARB treatment on the association between AT1RaAbs and functional measures and outcomes. Among older adults not receiving ARBs, there was an average 2.6 (95% CI, 0.52-4.68) kg decrease in grip strength for every 1 µg/mL increase in AT1RaAb level after adjusting for age. Multiple adjustments including sex, comorbidities, IL-6, and BMI, in addition to age, did not affect the association in older adults who did not receive ARBs: a decrease of 2.8 kg (95% CI, 0.67-4.93) for every 1 µg/mL increase in AT1RaAb, P<0.01. This relationship was not significant in older individuals receiving ARB treatment after age or other adjustments. The data are consistent with ARB treatment attenuating the negative effects of AT1RaAb on grip strength. The association between AT1RaAb levels and the natural logarithm of time to death was analyzed by multiple regression and split by ARB treatment and adjusted for age, sex, BMI, and BP. A β AT1RaAb of -0.097 (95% CI, -0.0158 to -0.036) and P<0.0001 was assessed for subjects not receiving ARBS, whereas a β AT1RaAb of 0.024 (95% CI, -0.057 to 0.106) and P=0.53 was obtained for those who were treated with ARBs. Consistent with the grip strength data, ARB treatment attenuated the association between time to death and AT1RaAb levels. These observations were unlikely to be caused by demographic or clinical differences between those on ARBs and not on ARBs, because the characteristics of Chicago group segregated by ARB treatment, with the exception of thyroid disease, were similar (Table 2) .
Elevated serum levels of AT1RaAbs have been clinically associated with preeclampsia. 9, 23, 24 The potential impact of past pregnancies and history of preeclampsia as factors that could alter AT1RaAb levels in our 2 groups (Chicago and Baltimore) was investigated. Participants enrolled in the Chicago group were recruited as part of the Chicago Religious Order Study. Women enrolled in this study were nuns with no reported history of pregnancy and children. Participants from the Baltimore population were surveyed for pregnancy history. There was no reported preeclampsia in female Baltimore participants, which was not surprising, given that the prevalence of preeclampsia is ≈3% of all pregnancies in the United States. 26 Furthermore, adjusting for past pregnancy history did not alter associations between AT1RaAb levels and functional measures. This was also supported by the observation that adjusting for sex did not change the association of AT1RaAb with the outcomes reported.
DISCUSSION
In 2 distinct groups, higher serum AT1RaAb levels were strongly associated with worse BP control, worse functional measures, and higher rates of falls and death.
To date, the relationship between RAS activation and lifespan remains unclear. 27 RAS blockade in some animal studies results in a 25% extension of lifespan, 28 and improved physical performance, as well. 29 However, the response to RAS blockade has varied widely in human studies of variable design. 30 Our data suggest that ARB treatment may modulate associations between AT1RaAb levels and physical performance measures and mortality. If these associations are confirmed, studies of RAS blockers might target individuals with high levels of these autoantibodies.
The correlation between IL-6, systolic BP, and serum AT1RaAb is in agreement with previous research documenting the role of inflammation in the development of hypertension and with a role for AT1RaAb as a prohypertensive autoantibody. 31, 32 It is not clear whether AT1RaAbs are specific disease-causing agents, or if their levels reflect age-related global dysregulation of autoantibody production. Autoantibodies, in general, are capable of stimulating receptors and causing disease, such as Graves disease 33 and dilated cardiomyopathy. 34 In our study, we observed an association between serum level of AT1RaAb and the proinflammatory cytokine IL-6 that has been linked to frailty 35, 36 ; functional measures associated with risk status (walking speed and grip strength); and poor outcomes (falls, death). The correlation coefficients for these associations were significant, although the percentage of variance in the outcome measure accounted for might be considered small, ranging from 9% to 32%. Grip strength, walking speed, and falls are complex traits, and correlations in the range of what we report are considered biologically significant. 37, 38 For example, the In Chianti study of inflammatory biomarkers and physical performance in 1020 participants aged ≥65 years found that C-reactive protein, IL-6, and interleukin-1 receptor antagonist were significantly correlated with physical performance (Spearman r=−0.162, r=−0.251, and r=−0.127, respectively) and walking speed (Spearman r=-0.143, r=-0.254, r=-0.133, respectively). A similar correlation (r=0.20) was seen in a study of myostatin and grip strength, and a biological linkage between myostatin and the outcome is evident. 39 Differences in serum levels of these autoantibodies may explain some of the variability in results of studies of RAS blockade for improving muscle strength and physical performance in older individuals. 7 Our exploratory data indicate that the use of ARBs attenuated the association between levels of AT1RaAb and decline in grip strength and time to death. Hints of this effect may be gleaned from previous reports documenting that ARBs may retard the decline in muscle strength and physical activity in older hypertensive persons. 40 Our data suggest that this effect may have been partially explained by the presence of AT1RaAb in these older adults. Analysis of the effect of ARB treatment on the association between autoantibody levels and number of falls yielded wide confidence intervals to the odds ratio that lost significance with any adjustment. The increased incidence of falls and serious injuries with the use of ARBs has been previously reported, 41 and this may have confounded our analysis. It may also be that the limited number of samples in the Chicago group negatively impacted the power of the analysis.
The present study and reports on the effects of AT1RaAb on cytokines, reactive oxygen species, and endothelial dysfunction 9-11 extend a line of evidence suggesting that elevated serum levels of AT1RaAb may have contributed to the precipitation and progression of physical decline in those older individuals at high risk for negative health outcomes (increased falls and mortality) and may do so via specific proinflammatory effects. Furthermore, patients with high levels of antibodies that stimulate AT1R may be more likely to benefit from ARB treatment that blocks AT1R. The limitations to this study include a relatively small validation group sample size that, although yielding statistical significance in our primary outcomes, impeded robust analyses of ARB effects on falls and mortality by subgroups. Perhaps more important is that the study is designed to ascertain associations, not causality. Larger studies are required to fine tune the use of AT1RaAb as a screening tool, and large intervention trials are needed to guide selection of individuals that might benefit most from RAS blockade.
In summary, the association of risk status with serum levels of AT1RaAb provides a plausible biological pathway for RAS-mediated chronic inflammation and subse- quent disease progression that can be probed for therapeutic intervention. ARB treatment was associated with a blunting of the harm seen in patients with high levels of agonistic autoantibodies to AT1R.
